Rheumatology

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.

In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.

David Charles, MD, highlights how alternative funding programs, though well-intentioned, can inadvertently erode trust between patients and providers and cause delays in healthcare.

Results of a recent study indicated rheumatology ultrasound clinics may play an increasingly central and dynamic role in rheumatology practices.

Stacie Bell, PhD, discusses the partnership between Lupus Therapeutics and AbbVie for the phase 3 clinical program of upadacitinib in patients with SLE, emphasizing the importance of collaboration and their role in accelerating the study process, recruitment, and the potential for meaningful advancements in lupus treatment.

Rosalind Ramsey-Goldman, MD, discusses her study, “The impact of US abortion policy on rheumatology clinical practice: a cross-sectional survey of rheumatologists.”

V Michael Holers, MD, discusses the creation of Rheumatology Lab in response to a pressing need within the clinical practice community to provide an easily accessible resource for physicians to guide patients to valuable information.

The introduction of an ICD-10 code specific to IgG4-Related Disease offers a promising opportunity to revolutionize patient care, enable more accurate diagnoses, and improve outcomes.

Many studies support the finding that biologic therapy reduces the presence of psoriatic arthritis—or the risk of developing arthritis in psoriatic patients—but other research suggest the opposite.

While Black people are consistently underrepresented, White people are consistently overrepresented in inflammatory arthritis trials for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.

Low allopurinol prescription rates and suboptimal dosing are of particular concern in adult patients in Asia with poorly controlled gout.

The use of SGLT2 inhibitors was associated with similar or lower risks of fractures as incretin-based drugs, even in the high-risk patient population.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

A nationwide cohort study shows individuals with a history of infection are at a nearly 50% greater likelihood of dementia development in older age.

On August 29, 2023, the Biden Administration debuted the list of the first 10 drugs identified for price negotiation under the Inflation Reduction Act. The list, which includes agents indicated for diabetes, heart failure, GI conditions, and arthritis, accounted for more than $50 billion in spending during the evaluation period.

Osteoporosis is estimated to affect 595 million patients worldwide, representing a 132% increase in total cases since 1990.

Guidelines aim to help the identification of ILD in patients with rheumatic disease and aid in improving the management of patients.

Granted to Ipsen, the breakthrough treatment reduces new, abnormal bone growth in people living with the ultra-rare bone disease.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Albert Roy, president of the Lupus Research Alliance, elaborates on recent initiatives designed to address the underrepresentation of minorities in lupus research.

Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.